FDA Safety Warning on the Cardiac Effects of Lamotrigine: An Advisory from the Ad Hoc ILAE/AES Task Force

This ILAE/AES joint advisory statement provides information for clinicians after the October 9, 2020, FDA addition of a safety warning related to patients with certain underlying cardiac disorders or arrhythmias to the prescribing information for lamotrigine.